HALO Clinical AI

Breast Macrodissect AI accurately identifies ductal carcinoma in situ (DCIS) and excludes this non-invasive region from invasive tumor analysis. Demonstrating the algorithm’s ability to differentiate between clinically relevant tissue architecture and improving molecular testing in breast cancer.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio

Clinical, HALO AP, HALO Clinical AI, HALO Macrodissect Solutions, News, Press Releases / , , , ,

Albuquerque, NM, February 10, 2025 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.

Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio Read More »

Looking Back: Reviewing 2025 at Indica Labs

Blogs, Breast IHC AI, Cloud Services, CRC Macrodissect AI, HALO, HALO AI, HALO AI Apps, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Link, Lung Macrodissect AI, News, Pharma Services, SlideQC BF / , , , , , , , , , ,

As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.

Looking Back: Reviewing 2025 at Indica Labs Read More »

The rapid global adoption of HALO AP® prompted immediate localization of the platform in Chinese, Danish, Dutch, American and British English, Finnish, French, German, Greek, Italian, Norwegian, Japanese, Portuguese, Russian, Spanish, Slovakian, and Swedish. Shown here are all 17 languages represented as each country's flags.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets

Breast IHC AI, HALO AP, HALO AP Dx, HALO Clinical AI, HALO Macrodissect Solutions, Lung Macrodissect AI, News, Press Releases / , , , , , , , ,

Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.

Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »

Free Demo
Free Demo
Scroll to Top